TSE:NVLN - Novelion Therapeutics Stock Price, News & Analysis

C$13.30
0.00 (0.00 %)
(As of 12/18/2018)
Add
Today's Range
C$13.30
Now: C$13.30
C$13.30
50-Day Range N/A
52-Week Range
C$10.68
Now: C$13.30
C$13.67
VolumeN/A
Average Volume3,220 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company's portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
CIKN/A
Phone+1-604-7077000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableOptionable

Receive NVLN News and Ratings via Email

Sign-up to receive the latest news and ratings for NVLN and its competitors with MarketBeat's FREE daily newsletter.


Novelion Therapeutics (TSE:NVLN) Frequently Asked Questions

What is Novelion Therapeutics' stock symbol?

Novelion Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "NVLN."

Has Novelion Therapeutics been receiving favorable news coverage?

Press coverage about NVLN stock has been trending positive this week, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novelion Therapeutics earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the next several days. View News Stories for Novelion Therapeutics.

What other stocks do shareholders of Novelion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novelion Therapeutics investors own include Alnylam Pharmaceuticals (ALNY), NXP Semiconductors (NXPI), Whole Foods Market (WFM), InvenSense (INVN), Opko Health (OPK), Vitamin Shoppe (VSI), Veru (VERU), Novavax (NVAX), GW Pharmaceuticals PLC- (GWPH) and Gilead Sciences (GILD).

How do I buy shares of Novelion Therapeutics?

Shares of NVLN and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Novelion Therapeutics' stock price today?

One share of NVLN stock can currently be purchased for approximately C$13.30.

What is Novelion Therapeutics' official website?

The official website for Novelion Therapeutics is http://www.novelion.com/.

How can I contact Novelion Therapeutics?

Novelion Therapeutics' mailing address is 1800-510 Georgia St W, VANCOUVER, BC V6B 0M3, Canada. The company can be reached via phone at +1-604-7077000.


MarketBeat Community Rating for Novelion Therapeutics (TSE NVLN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  91 (Thanks for Voting!)
Underperform Votes:  66 (Thanks for Voting!)
Total Votes:  157
MarketBeat's community ratings are surveys of what our community members think about Novelion Therapeutics and other stocks. Vote "Outperform" if you believe NVLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel